Waterdrop Inc. Announces Second Quarter 2023 Unaudited Financial Results
- First-year premiums increased by 29.8% QoQ to RMB2,197.0 million ($303.0 million). Net operating revenue increased by 12.0% QoQ to RMB678.7 million ($93.6 million). Cash and cash equivalents amounted to RMB3,399.2 million ($468.8 million).
- Insurance-related income decreased by 4.6% YoY to RMB597.4 million ($82.4 million). Crowdfunding service fees decreased by 20.3% YoY to RMB44.7 million ($6.2 million). Operating loss was RMB41.6 million ($5.7 million).
- None.
Financial and Operational Highlights for the Second Quarter of 2023
- Resilient business performance: For the second quarter of 2023, the first-year premiums ("FYP") generated through our Waterdrop Insurance Marketplace amounted to
RMB2,197.0 million (US ), representing an increase of$303.0 million 29.8% quarter over quarter. Our net operating revenue wasRMB678.7 million (US ), representing an increase of$93.6 million 12.0% quarter over quarter. - Positive operating cash flow: As of June 30, 2023, our cash and cash equivalents and short-term investments balance amounted to
RMB3,399.2 million (US ). We continued to generate positive operating cash flow, and have cash outflow of investing and financing activities.$468.8 million - Further expanded product offerings: As of June 30, 2023, we offered 1,050 insurance products on our platform, as compared with 876 as of March 31, 2023. In the second quarter of 2023, the FYP generated from critical illness insurance products accounted for
21.8% of overall FYP generated through our Waterdrop Insurance Marketplace. - As of June 30, 2023, around 439 million people cumulatively had donated an aggregate of approximately
RMB60.1 billion to over 2.95 million patients through Waterdrop Medical Crowdfunding.
Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "In the second quarter, we continued on a high-quality user-centric development trajectory, achieving a net operating revenue of
In the second quarter, our insurance business witnessed a sequential growth in the number of new users and maintained a consistently high policy renewal rate. Meanwhile, we continued to innovate on product offerings and unveiled the Blue Ocean Lifetime Health Insurance, a groundbreaking medical insurance policy that facilitates connections to pioneering overseas medical interventions and pharmaceuticals.
As for the medical crowdfunding business, our Operational Transparency Committee continuously monitored the authenticity of fundraising activities, safeguarding the rights of patients and donors. We also further refined our consultant services, as part of the efforts to promote industry best practices and the orderly development of the entire sector.
E-Find Platform maintained a high growth momentum. In the second quarter, we collaborated with 132 pharmaceutical companies and CROs and successfully enrolled more than 900 patients. We also onboarded 80 new clinical trial programs, a testament to our solid performance in digital patient recruiting. It is worth noting that during this quarter our CRO business achieved significant progress by initiating the first full-cycle clinical trial operation project.
Looking forward, we will continue to integrate resources and maximize our advantages in the domestic insurance and healthcare industry."
Financial Results for the Second Quarter of 2023
Operating revenue, net
Net operating revenue for the second quarter of 2023 decreased by
- Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to
RMB597.4 million (US ) in the second quarter of 2023, representing a decrease of$82.4 million 4.6% year over year fromRMB625.9 million for the second quarter of 2022, which was mainly due to the decrease in technical service income. - Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. Since April 7, 2022, our crowdfunding platform has ceased to fully subsidize the related cost and started to charge a service fee of
3% of the funds raised, up to a maximum amount ofRMB5,000 for a single campaign. Considering the specific situation of each case, we may selectively subsidize the service fee for certain patients with special needs. For the second quarter of 2023, we generatedRMB44.7 million (US ) in service fees, representing a decrease of$6.2 million 20.3% year over year fromRMB56.1 million for the second quarter of 2022. - Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the second quarter of 2023, our clinical trial solution income amounted to
RMB29.4 million (US ), as compared to$4.0 million RMB11.0 million in the same period of 2022.
Operating costs and expenses
Operating costs and expenses increased by
- Operating costs increased by
36.2% year over year toRMB333.1 million (US ) for the second quarter of 2023, as compared with$45.9 million RMB244.6 million for the second quarter of 2022, which was primarily driven by (i) aRMB74.2 million increase in costs of referral and service fees, and (ii) aRMB8.9 million increase in the costs for patient recruitment consultants team. On a quarter-over-quarter basis, operating costs increased by34.3% in the second quarter of 2023, primarily due to theRMB60.9 million increase in costs of referral and service fees. - Sales and marketing expenses increased by
41.6% year over year toRMB204.5 million (US ) for the second quarter of 2023, as compared with$28.2 million RMB144.4 million for the same quarter of 2022. The increase was primarily due to an increase ofRMB50.7 million in marketing expenses to third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by18.0% in the second quarter of 2023, primarily due to theRMB29.0 million increase in marketing expenses to third-party traffic channels partially offset byRMB8.6 million decrease in share-based compensation expenses. - General and administrative expenses increased by
11.6% year over year toRMB96.0 million (US ) for the second quarter of 2023, compared with$13.2 million RMB86.1 million for the same quarter of 2022. The year-over-year variance was due to an increase ofRMB9.9 million in professional service fees. On a quarter-over-quarter basis, general and administrative expenses remained stable, due to the increase ofRMB10.1 million professional service fees, offset by the decrease ofRMB8.3 million in share-based compensation expenses. - Research and development expenses increased by
23.1% year over year toRMB86.7 million (US ) for the second quarter of 2023, compared with$12.0 million RMB70.4 million for the same period of 2022. The increase was primarily due toRMB15.0 million increases in research and development personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, research and development expenses increased by10.2% fromRMB78.7 million , which was mainly due toRMB6.5 million increases in research and development personnel costs and share-based compensation expenses.
Operating loss for the second quarter of 2023 was
Interest income for the second quarter of 2023 was
Income tax benefit for the second quarter of 2023 was
Net profit attributable to Waterdrop for the second quarter of 2023 was
Adjusted net profit attributable to Waterdrop for the second quarter of 2023 was
Cash and cash equivalents and short-term investments
As of June 30, 2023, the Company had combined cash and cash equivalents and short-term investments of
Share Repurchase Plans
Pursuant to the share repurchase program launched in September 2021 and amended in September 2022, as of August 31, 2023, we cumulatively repurchased approximately 37.5 million ADSs from the open market with cash for a total consideration of approximately
On September 6, 2023, the board of the Company (the "Board") has approved a new share repurchase program. Under the new program, the Company is authorized to repurchase its own ordinary shares in the form of American depository shares with an aggregate value of up to
Supplemental Information
Prior to this quarter, we operated and managed our business as a single segment. Starting from the second quarter of 2023, our chief operating decision makers start to manage the business by three operating segments and assess the performance and allocate resources under the new operating segment structure.
Therefore, we organize and report our business in three operating segments:
- Insurance, which mainly includes Waterdrop Insurance Marketplace and technical support service;
- Crowdfunding, which mainly includes Waterdrop Medical Crowdfunding; and
- Others, which mainly include Digital Clinical Trial Solution and other new initiatives.
As a result, we have updated our segments reporting information to reflect the new operating and reporting structure.
Comparative figures were retrospectively adjusted to conform to this presentation.
For the Three Months Ended | For the Six Months Ended | ||||||||||||||||
June 30, 2022 | March 31, 2023 | June 30, 2023 | June 30, 2022 | June 30, 2023 | |||||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | |||||||||||
(All amounts in thousands) | |||||||||||||||||
Operating revenue, net | |||||||||||||||||
Insurance | 625,927 | 536,343 | 597,437 | 82,390 | 1,254,162 | 1,133,780 | 156,355 | ||||||||||
Crowdfunding | 56,061 | 42,022 | 44,677 | 6,161 | 56,061 | 86,699 | 11,956 | ||||||||||
Others | 19,430 | 27,800 | 36,586 | 5,046 | 39,883 | 64,386 | 8,880 | ||||||||||
Total consolidated operating revenue, net | 701,418 | 606,165 | 678,700 | 93,597 | 1,350,106 | 1,284,865 | 177,191 | ||||||||||
Operating profit/(loss) | |||||||||||||||||
Insurance | 270,843 | 154,955 | 99,759 | 13,757 | 551,687 | 254,714 | 35,127 | ||||||||||
Crowdfunding | (45,783) | (61,134) | (64,131) | (8,844) | (150,336) | (125,265) | (17,275) | ||||||||||
Others | (43,392) | (36,567) | (47,877) | (6,603) | (80,031) | (84,444) | (11,647) | ||||||||||
Total segment operating profit/(loss) | 181,668 | 57,254 | (12,249) | (1,690) | 321,320 | 45,005 | 6,205 | ||||||||||
Unallocated item* | (25,745) | (46,926) | (29,393) | (4,053) | (48,752) | (76,319) | (10,525) | ||||||||||
Total consolidated operating profit/(loss) | 155,923 | 10,328 | (41,642) | (5,743) | 272,568 | (31,314) | (4,320) | ||||||||||
Total other income | 31,264 | 36,771 | 52,835 | 7,287 | 70,898 | 89,606 | 12,357 | ||||||||||
Profit before income tax | 187,187 | 47,099 | 11,193 | 1,544 | 343,466 | 58,292 | 8,037 | ||||||||||
Income tax benefit/(expense) | 19,756 | 2,626 | 10,504 | 1,449 | (31,565) | 13,130 | 1,811 | ||||||||||
Net profit | 206,943 | 49,725 | 21,697 | 2,993 | 311,901 | 71,422 | 9,848 | ||||||||||
* The share-based compensation represents an unallocated item in the segment information because our management does not consider this as part of the segment operating performance measure. |
Recent Development
Status Update of Acquisition of Cunzhen Qiushi
Since the previously announced acquisition plan of Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries (collectively, "Cunzhen Qiushi", also known as "Shenlanbao") on June 9, 2023, the Company, as planned, firstly acquired
Exchange Rate
This announcement contains translations of certain RMB amounts into
Non-GAAP Financial Measure
The Company uses non-GAAP financial measure, adjusted net profit, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit represents net profit excluding share-based compensation expense and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.
The non-GAAP financial measure is not presented in accordance with
The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable
For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the
Conference Call Information
Waterdrop's management team will hold a conference call on September 7, 2023 at 8:00 AM
International: | 1-412-317-6061 |
United States Toll Free: | 1-888-317-6003 |
Hong Kong Toll Free: | 800-963976 |
852-58081995 | |
Mainland | 4001-206115 |
Chinese Line (Mandarin) Entry Number: | 6407234 |
English Interpretation Line (Listen-only Mode) Entry Number: | 6030724 |
Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.
Telephone replays will be accessible two hours after the conclusion of the conference call through September 14, 2023 by dialing the following numbers:
United States Toll Free: | 1-877-344-7529 |
International: | 1-412-317-0088 |
Chinese Line Access Code: | 4181965 |
English Interpretation Line Access Code: | 3440853 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.
About Waterdrop Inc.
Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.
For investor inquiries, please contact
Waterdrop Inc.
IR@shuidi-inc.com
WATERDROP INC. | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(All amounts in thousands, unless otherwise noted) | |||||
As of | |||||
December 31,2022 | June 30,2023 | ||||
RMB | RMB | USD | |||
Assets | |||||
Current assets | |||||
Cash and cash equivalents | 1,574,171 | 644,340 | 88,859 | ||
Restricted cash | 517,364 | 536,890 | 74,041 | ||
Short-term investments | 2,130,377 | 2,754,859 | 379,912 | ||
Accounts receivable, net | 675,796 | 836,777 | 115,397 | ||
Current contract assets | 450,085 | 471,233 | 64,986 | ||
Amount due from related parties | 358 | 240 | 33 | ||
Prepaid expense and other assets | 342,468 | 255,534 | 35,241 | ||
Total current assets | 5,690,619 | 5,499,873 | 758,469 | ||
Non-current assets | |||||
Non-current contract assets | 103,591 | 110,460 | 15,233 | ||
Property, equipment and software, net | 31,397 | 33,898 | 4,675 | ||
Intangible assets, net | 56,614 | 56,571 | 7,801 | ||
Long-term investments | 11,969 | 98,586 | 13,596 | ||
Right of use assets, net | 18,447 | 68,186 | 9,403 | ||
Deferred tax assets | 6,166 | 9,796 | 1,351 | ||
Goodwill | 3,420 | 3,420 | 472 | ||
Total non-current assets | 231,604 | 380,917 | 52,531 | ||
Total assets | 5,922,223 | 5,880,790 | 811,000 | ||
Liabilities and Shareholders' Equity | |||||
Current liabilities | |||||
Amount due to related parties | 11,553 | 11,734 | 1,618 | ||
Insurance premium payables | 516,661 | 555,903 | 76,663 | ||
Accrued expenses and other current liabilities | 584,123 | 627,347 | 86,515 | ||
Current lease liabilities | 9,354 | 30,229 | 4,169 | ||
Total current liabilities | 1,121,691 | 1,225,213 | 168,965 | ||
Non-current liabilities | |||||
Non-current lease liabilities | 4,701 | 37,899 | 5,227 | ||
Deferred tax liabilities | 29,703 | 15,700 | 2,165 | ||
Total non-current liabilities | 34,404 | 53,599 | 7,392 | ||
Total liabilities | 1,156,095 | 1,278,812 | 176,357 | ||
Shareholders' equity | |||||
Class A ordinary shares | 108 | 111 | 15 | ||
Class B ordinary shares | 27 | 27 | 4 | ||
Treasury stock | (3) | (9) | (1) | ||
Additional paid-in capital | 7,384,670 | 7,085,097 | 977,080 | ||
Accumulated other comprehensive income | 108,245 | 174,514 | 24,067 | ||
Accumulated deficit | (2,726,919) | (2,657,762) | (366,522) | ||
Total shareholders' equity | 4,766,128 | 4,601,978 | 634,643 | ||
Total liabilities and shareholders' equity | 5,922,223 | 5,880,790 | 811,000 |
WATERDROP INC. | ||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | ||||||||||||||
(All amounts in thousands, except for share and per share data, or otherwise noted) | ||||||||||||||
For the Three Months Ended | For the Six Months Ended | |||||||||||||
June 30, 2022 | March 31, 2023 | June 30, 2023 | June 30, 2022 | June 30, 2023 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Operating revenue, net | 701,418 | 606,165 | 678,700 | 93,597 | 1,350,106 | 1,284,865 | 177,191 | |||||||
Operating costs and expenses(i) | ||||||||||||||
Operating costs | (244,616) | (247,983) | (333,140) | (45,942) | (399,496) | (581,123) | (80,141) | |||||||
Sales and marketing expenses | (144,423) | (173,401) | (204,548) | (28,208) | (348,766) | (377,949) | (52,122) | |||||||
General and administrative expenses | (86,054) | (95,798) | (95,997) | (13,239) | (188,049) | (191,795) | (26,450) | |||||||
Research and development expenses | (70,402) | (78,655) | (86,657) | (11,951) | (141,227) | (165,312) | (22,798) | |||||||
Total operating costs and expenses | (545,495) | (595,837) | (720,342) | (99,340) | (1,077,538) | (1,316,179) | (181,511) | |||||||
Operating profit/(loss) | 155,923 | 10,328 | (41,642) | (5,743) | 272,568 | (31,314) | (4,320) | |||||||
Other income | ||||||||||||||
Interest income | 15,213 | 30,876 | 37,618 | 5,188 | 29,705 | 68,494 | 9,446 | |||||||
Foreign currency exchange gain | 163 | 282 | 838 | 116 | 816 | 1,120 | 154 | |||||||
Others, net | 15,888 | 5,613 | 14,379 | 1,983 | 40,377 | 19,992 | 2,757 | |||||||
Profit before income tax | 187,187 | 47,099 | 11,193 | 1,544 | 343,466 | 58,292 | 8,037 | |||||||
Income tax benefit/(expense) | 19,756 | 2,626 | 10,504 | 1,449 | (31,565) | 13,130 | 1,811 | |||||||
Net profit attributable to Waterdrop Inc. | 206,943 | 49,725 | 21,697 | 2,993 | 311,901 | 71,422 | 9,848 | |||||||
Net profit attributable to ordinary shareholders | 206,943 | 49,725 | 21,697 | 2,993 | 311,901 | 71,422 | 9,848 | |||||||
Net profit | 206,943 | 49,725 | 21,697 | 2,993 | 311,901 | 71,422 | 9,848 | |||||||
Other comprehensive income: | ||||||||||||||
Foreign currency translation adjustment, net of tax | 83,901 | 3,386 | 64,434 | 8,886 | 76,118 | 67,820 | 9,353 | |||||||
Unrealized gains/(loss) on available for sale investments, net of tax | 3,100 | 1,957 | (3,508) | (484) | 4,172 | (1,551) | (214) | |||||||
Total Comprehensive income | 293,944 | 55,068 | 82,623 | 11,395 | 392,191 | 137,691 | 18,987 | |||||||
Weighted average number of ordinary shares used in computing | ||||||||||||||
Basic | 3,926,602,657 | 3,866,785,745 | 3,795,521,186 | 3,795,521,186 | 3,932,647,108 | 3,831,316,817 | 3,831,316,817 | |||||||
Diluted | 4,006,060,346 | 4,027,428,601 | 3,949,592,050 | 3,949,592,050 | 4,009,442,628 | 3,988,673,677 | 3,988,673,677 | |||||||
Net profit per share attributable to ordinary shareholders | ||||||||||||||
Basic | 0.05 | 0.01 | 0.01 | 0.00 | 0.08 | 0.02 | 0.00 | |||||||
Diluted | 0.05 | 0.01 | 0.01 | 0.00 | 0.08 | 0.02 | 0.00 | |||||||
(i) Share-based compensation expenses are included in the operating costs and expenses as follows. | ||||||||||||||
For the Three Months Ended | For the Six Months Ended | |||||||||||||
June 30, 2022 | March 31, 2023 | June 30, 2023 | June 30, 2022 | June 30, 2023 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Sales and marketing expenses | (1,771) | (16,529) | (7,888) | (1,088) | (4,573) | (24,417) | (3,367) | |||||||
General and administrative expenses | (19,976) | (26,460) | (18,122) | (2,499) | (36,897) | (44,582) | (6,148) | |||||||
Research and development expenses | (3,998) | (3,937) | (3,383) | (466) | (7,282) | (7,320) | (1,010) | |||||||
Total | (25,745) | (46,926) | (29,393) | (4,053) | (48,752) | (76,319) | (10,525) |
WATERDROP INC. | ||||||||||||||
RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS | ||||||||||||||
(All amounts in thousands, unless otherwise noted) | ||||||||||||||
For the Three Months Ended | For the Six Months Ended | |||||||||||||
June 30, 2022 | March 31, 2023 | June 30, 2023 | June 30, 2022 | June 30, 2023 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Net profit | 206,943 | 49,725 | 21,697 | 2,993 | 311,901 | 71,422 | 9,848 | |||||||
Add: | ||||||||||||||
Share-based compensation expense | 25,745 | 46,926 | 29,393 | 4,053 | 48,752 | 76,319 | 10,525 | |||||||
Foreign currency exchange gain | (163) | (282) | (838) | (116) | (816) | (1,120) | (154) | |||||||
Adjusted net profit | 232,525 | 96,369 | 50,252 | 6,930 | 359,837 | 146,621 | 20,219 |
View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-announces-second-quarter-2023-unaudited-financial-results-301920399.html
SOURCE Waterdrop Inc.